(1,2-(13)C2-3-(15)N) lorazepam | 907200-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (1,2-(13)C2-3-(15)N) lorazepam
• 英文别名: Lorazepam-13C2,15N；7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 907200-04-8
• 化学式: C₁₅H₁₀Cl₂N₂O₂
• 分子量: 324.134
• InChiKey: DIWRORZWFLOCLC-XPGGNPKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  61.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Registry Method and Control System for Dea Schedule II-V Medicines
  申请人：Reis Alan J

  公开号：US20090208413A1

  公开（公告）日：2009-08-20

  The present invention provides compositions and methods for synthesizing labeled drugs. The present invention further provides methods for preventing or stopping prescription drug abuse for all agents registered as a Drug Enforcement Agency (DEA) schedule II through schedule V medications. According to the present invention, methods are provided for monitoring patient compliance with prescribed drug treatment. The present invention also provides methods for facilitating a replacement prescription when a patient is left without access to their prescribed drug. Furthermore, the present invention provides a method to improve employee compliance with an employer's drug policies via either a voluntary or compulsory system for enhanced drug testing.

  本发明提供了合成标记药物的组合物和方法。本发明还提供了预防或停止所有注册为药品执法局（DEA）II至V级药物的处方药物滥用的方法。根据本发明，提供了用于监测患者遵守规定的药物治疗方法。本发明还提供了在患者无法使用其处方药物时促进替代处方的方法。此外，本发明提供了一种通过自愿或强制性的增强药物测试系统来提高雇员遵守雇主药物政策的方法。